透皮给药制剂在阿尔茨海默症中的研究进展
摘要
阿尔茨海默症(AD)是一种常见、渐进、致命的神经退行性疾病,在日趋加剧的老龄化社会中影响严重。目前常用的抗AD药物主要有胆碱酯酶抑制剂和非竞争性N-甲基-D-天冬氨酸受体拮抗剂。然而,此类口服抗AD药物存在一些缺点,如血药浓度不稳定、患者依从性差、不良反应严重、首过代谢率高等,这些缺点导致其治疗效果不佳。透皮给药可以弥补口服抗AD药物的诸多缺点,提供稳定的药物扩散、避免首过代谢、减少胃肠系统的不良反应等。本文综述了抗AD药物经皮给药技术,旨在为抗AD药物透皮给药途径的研究提供一定的参考。
引文
[1]Behl C. The search for novel avenues for the therapy and prevention of Alzheimer's disease[J]. Drug News&Perspectives,2006,19(1):5.
[2]Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia[J]. International Journal of Clinical Practice Supplement,2002,127(127):45.
[3]AARP. Pharmaceutical Research and Manufacturers of America[J]. Chain Drug Review,2003,17(2):79-81.
[4]M. D. Lindner,Mcarthur R A,Deadwyler S A,et al.Development,Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease[J]. Animal&Translational Models for Cns Drug Discovery,2008:93-157.
[5]Davis B,Sadik K. Circadian Cholinergic Rhythms:Implications for Cholinesterase Inhibitor Therapy[J]. Dementia and Geriatric Cognitive Disorders,2006,21(2):120-129.
[6]Imbimbo D B P. Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer’s Disease[J]. CNS Drugs,2001,15(5):375-390.
[7]Somani S M,Dube S N. Physostigmine-an overview as pretreatment drug for organophosphate intoxication[J]. International Journal of Clinical Pharmacology Therapy&Toxicology,1989,27(8):367.
[8]Levy A,Brandeis R,Treves T A,et al. Transdermal Physostigmine in the Treatment of Alzheimer’s Disease[J]. Alzheimer Disease&Associated Disorders,1994,8(1):15-21.
[9]Moller H J,Hampel H,Hegerl U,et al. DoubleBlind,Randomized, Placebo-Controlled Clinical Trial on the Efficacy and Tolerability of a Physostigmine Patch in Patients with Senile Dementia of the Alzheimer Type[J]. Pharmacopsychiatry,1999,32(3):99-106.
[10]Benech H,Vincenti M,Fouchart F,et al. Development and in vivo assessment of a transdermal system for physostigmine[J]. Methods and Findings in Experimental and Clinical Pharmacology,1998,20(6):489-498.
[11]Riviere J E,Al E. Effects of vasoactive drugs on transdermal lidocaine iontophoresis[J]. J Pharm Sci,2010,80(7):615-620.
[12]Greenspoon J,Herrmann N,Adam D N. Transdermal rivastigmine:management of cutaneous adverse events and review of the literature[J]. Cns Drugs,2011,25(7):575.
[13]Yu Z W,Liang Y,Liang W Q. Low-frequency sonophoresis enhances rivastigmine permeation in vitro and in vivo[J]. Die Pharmazie,2015,70(6):379-80.
[14]Kim K H,Gwak H S. Effects of vehicles on the percutaneous absorption of donepezil hydrochloride across the excised hairless mouse skin[J]. Drug Development and Industrial Pharmacy,2011,37(9):1125-1130.
[15]Kim J Y,Han M R,Kim Y H,et al. Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer’s disease[J]. European Journal of Pharmaceutics and Biopharmaceutics,2016,105:148-155.
[16]Park C W,Son D D,Kim J Y,et al. Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system[J].International Journal of Pharmaceutics,2012,436(1-2):32-40.
[17]Marum R J V. Update on the use of memantine in Alzheimer’s disease[J]. Neuropsychiatric Disease&Treatment,2009,5(1):237.
[18]Lee,Sooa Han,Kim,et al. Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats[J]. Basic&Clinical Pharmacology&Toxicology,2016,118(2):122-127.
[19]Matsuo K,Okamoto H,Kawai Y,et al. Vaccine efficacy of transcutaneous immunization with amyloidβusing a dissolving microneedle array in a mouse model of Alzheimer’s disease[J]. Journal of Neuroimmunology,2014,266(1-2):1-11.
[20]Ye J C,Zeng S,Zheng G L,et al. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs[J]. International Journal of Pharmaceutics,2008,356(1):187-192.
[21]Moghaddam A A,Aqil M,Ahmad F J,et al. Nanoethosomes mediated transdermal delivery of vinpocetine for management of Alzheimer’s disease[J].Drug Delivery,2014,22(8):1-9.
[22]Shi J,Wang Y,Luo G. Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease,in vitro and in animal model studies[J]. AAPS PharmSciT ech,2012,13(2):485-492.
[2]Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia[J]. International Journal of Clinical Practice Supplement,2002,127(127):45.
[3]AARP. Pharmaceutical Research and Manufacturers of America[J]. Chain Drug Review,2003,17(2):79-81.
[4]M. D. Lindner,Mcarthur R A,Deadwyler S A,et al.Development,Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease[J]. Animal&Translational Models for Cns Drug Discovery,2008:93-157.
[5]Davis B,Sadik K. Circadian Cholinergic Rhythms:Implications for Cholinesterase Inhibitor Therapy[J]. Dementia and Geriatric Cognitive Disorders,2006,21(2):120-129.
[6]Imbimbo D B P. Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer’s Disease[J]. CNS Drugs,2001,15(5):375-390.
[7]Somani S M,Dube S N. Physostigmine-an overview as pretreatment drug for organophosphate intoxication[J]. International Journal of Clinical Pharmacology Therapy&Toxicology,1989,27(8):367.
[8]Levy A,Brandeis R,Treves T A,et al. Transdermal Physostigmine in the Treatment of Alzheimer’s Disease[J]. Alzheimer Disease&Associated Disorders,1994,8(1):15-21.
[9]Moller H J,Hampel H,Hegerl U,et al. DoubleBlind,Randomized, Placebo-Controlled Clinical Trial on the Efficacy and Tolerability of a Physostigmine Patch in Patients with Senile Dementia of the Alzheimer Type[J]. Pharmacopsychiatry,1999,32(3):99-106.
[10]Benech H,Vincenti M,Fouchart F,et al. Development and in vivo assessment of a transdermal system for physostigmine[J]. Methods and Findings in Experimental and Clinical Pharmacology,1998,20(6):489-498.
[11]Riviere J E,Al E. Effects of vasoactive drugs on transdermal lidocaine iontophoresis[J]. J Pharm Sci,2010,80(7):615-620.
[12]Greenspoon J,Herrmann N,Adam D N. Transdermal rivastigmine:management of cutaneous adverse events and review of the literature[J]. Cns Drugs,2011,25(7):575.
[13]Yu Z W,Liang Y,Liang W Q. Low-frequency sonophoresis enhances rivastigmine permeation in vitro and in vivo[J]. Die Pharmazie,2015,70(6):379-80.
[14]Kim K H,Gwak H S. Effects of vehicles on the percutaneous absorption of donepezil hydrochloride across the excised hairless mouse skin[J]. Drug Development and Industrial Pharmacy,2011,37(9):1125-1130.
[15]Kim J Y,Han M R,Kim Y H,et al. Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer’s disease[J]. European Journal of Pharmaceutics and Biopharmaceutics,2016,105:148-155.
[16]Park C W,Son D D,Kim J Y,et al. Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system[J].International Journal of Pharmaceutics,2012,436(1-2):32-40.
[17]Marum R J V. Update on the use of memantine in Alzheimer’s disease[J]. Neuropsychiatric Disease&Treatment,2009,5(1):237.
[18]Lee,Sooa Han,Kim,et al. Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats[J]. Basic&Clinical Pharmacology&Toxicology,2016,118(2):122-127.
[19]Matsuo K,Okamoto H,Kawai Y,et al. Vaccine efficacy of transcutaneous immunization with amyloidβusing a dissolving microneedle array in a mouse model of Alzheimer’s disease[J]. Journal of Neuroimmunology,2014,266(1-2):1-11.
[20]Ye J C,Zeng S,Zheng G L,et al. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs[J]. International Journal of Pharmaceutics,2008,356(1):187-192.
[21]Moghaddam A A,Aqil M,Ahmad F J,et al. Nanoethosomes mediated transdermal delivery of vinpocetine for management of Alzheimer’s disease[J].Drug Delivery,2014,22(8):1-9.
[22]Shi J,Wang Y,Luo G. Ligustrazine phosphate ethosomes for treatment of Alzheimer's disease,in vitro and in animal model studies[J]. AAPS PharmSciT ech,2012,13(2):485-492.